Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Acta haematologica·2019
Same author

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Cancer·2019
Same author

Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2017
Same author

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2017
Same author

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Clinical lymphoma, myeloma & leukemia·2017
Same author

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Cancer·2016

Related Experiment Videos

Bendamustine therapy in chronic lymphocytic leukemia.

David Masiello1, Anil Tulpule

  • 1USC Keck School of Medicine, Norris Cancer Center, Jane Ann Nohl Division of Hematology and Center for Blood Disease, Department of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA. masiello@usc.edu

Expert Opinion on Pharmacotherapy
|June 17, 2009
PubMed
Summary

Bendamustine, a drug with alkylating and purine analog properties, is effective for chronic lymphocytic leukemia. Its dual action provides therapeutic benefits and helps understand its adverse effects.

Related Experiment Videos

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Bendamustine is approved for chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
  • Its efficacy in solid tumors is under investigation.

Purpose of the Study:

  • To understand the therapeutic benefits and adverse effects of bendamustine.
  • To explore the bi-functionality of bendamustine.

Main Methods:

  • Review of relevant biochemistry and molecular biology pathways.
  • Analysis of bendamustine activity in human clinical trials.

Main Results:

  • Bendamustine exhibits both alkylating and purine analogue properties.
  • Limited cross-reactivity observed with other purine analogs and alkylators.

Conclusions:

  • Bendamustine's dual mechanism makes it effective for chronic lymphocytic leukemia.
  • Understanding its pathways is key to its therapeutic application.